Our scientific platform is on the cutting edge of molecular imaging technology providing Precision as a Service™

Molecular imaging is the visualization, characterization, and measurement of biological processes at the molecular and cellular levels in patients and other living systems.  It is non-invasive, quantitative and can be performed repeatedly.  Unlike anatomic imaging, such as magnetic resonance (MR) imaging and computed tomography (CT), molecular imaging measures physiology and function with the potential to uncover disease at an earlier stage when it might still be contained and treatable. 

Molecular imaging uses drugs that can be visualized, such as radiopharmaceuticals, which are essentially radioactive drugs that are administered to the patient and detected using several imaging modalities, the most clinically prevalent of which is positron emission tomography (PET).  An advantage of radiopharmaceutical-based techniques is the ability to change – within the same agent – from an imaging isotope, such as fluorine-18, to a therapeutic isotope, such as astatine-211.  That encompasses the “theranostic” concept, whereby imaging and therapy can be performed with nearly identical agents.  Precision Molecular, Inc. is a clinical-phase company with radiopharmaceutical and theranostic products to help manage cancer.

“We focus on high-value theranostic targets for tumors and their microenvironment. The latter is increasingly recognized as a key factor in promoting malignancy, and reprogramming it against the tumor is among our most important objectives.”

— Martin Pomper | Founder, PMI